Isomorphic Labs raises record $5B Series C as president lays out AI-first drug design vision
快鲤鱼 · wechat · 2026-11-22
Alphabet's AI drug discovery company Isomorphic Labs closed a record $5 billion Series C led by Greenoaks and Sequoia, with a16z joining and Alphabet reinvesting—just six months after a $2.1B Series B. Spun out of DeepMind in 2021 by Nobel laureate Demis Hassabis, the company aims to build a general AI drug-design engine that moves drug discovery from real-world trial and error to computer simulation.
The article centers on a NoPriors podcast interview with president Max Jaderberg, who traced his path from an Oxford computer vision PhD and a 2014 ImageNet-winning model to DeepMind. His core thesis: pharma remains empirical and trial-heavy, with costs around $1.5B per drug and 15-year timelines while approvals stagnate. Isomorphic benchmarks every model against real experimental accuracy, aiming to run most molecular design and iteration in silico—including preclinical toxicity prediction—so lab work has a far higher success rate, and R&D knowledge compounds into true economies of scale.
More from Companies & People
- From twttr to X: a visual history of Twitter's logo across 19 years — ThePeterMick · 2026-11-22
- Ben Todd pushes back: Epoch ECI is math-driven, so was Anthropic really behind on agentic coding? — ben_j_todd · 2026-11-22
- Sarcasm online as Nvidia engineers reportedly leave in droves — kevinnbass · 2026-11-22
- Do frontier labs' exit agreements silence employees' conscientious objections? — BlackHC · 2026-11-22
- Musk warns of AI funding crunch; Tao says RH proof needs time to digest — 快鲤鱼 · 2026-11-22
- Claude users banned 4 days after billing turn to Washington AG as Anthropic refunds stall — lxfater · 2026-11-22